ReviewFrontiers in oncology2021
The Role of Sphingolipids Metabolism in Cancer Drug Resistance.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 54 citations in OpenAlex.
- Function ofInsects · 2026Article
- Spatial lipidomics with in situ segmentation for profiling doxorubicin drug effect of hepatoma carcinoma cell spheroids.Analytical and bioanalytical chemistry · 2026Article
- Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants.International journal of molecular sciences · 2026Article
- SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment.CNS neuroscience & therapeutics · 2026Article
- A Rare Case Report of Immunoglobulin D Subtype Multiple Myeloma Complicated With Hyperlipidemia.Case reports in hematology · 2026Article
- Sphingolipid-associated signature unveils TIMP1-driven temozolomide resistance and guides stratified therapy in glioblastoma.Frontiers in immunology · 2026Article
- Heterogeneity of common carotid artery and abdominal aorta: an angle of sphingolipid metabolism in vascular smooth muscle cells.Biomedical engineering online · 2025Article
- Cholangiocarcinoma cells direct fatty acids to support membrane synthesis and modulate macrophage phenotype.Hepatology communications · 2025Article
- Differential Effects of Sphingolipids on Cell Death and Antioxidant Defenses in Type 1 and Type 2 Endometrial Cancer Cells.International journal of molecular sciences · 2025Article
- Drug Resistance: The Role of Sphingolipid Metabolism.International journal of molecular sciences · 2025Review
- Impact of Excess Activin A on the Lipids, Metabolites, and Steroids of Adult Mouse Reproductive Organs.Endocrinology · 2025Article
- Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings.Cancer metastasis reviews · 2025Review
- Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells.International journal of molecular sciences · 2025Article
- SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway.Cell death discovery · 2025Article
- Sphingolipid Metabolism Dysregulation Drives Immune Microenvironment Remodeling and Predicts Prognosis in Bladder Cancer.International journal of genomics · 2025Article
- Development and validation of a machine learning-driven mitochondrial gene signature for the diagnosis of breast cancer.Frontiers in immunology · 2025Article
- Multiomics analyses of human colorectal cancer reveal changes in mitochondrial metabolism associated with chemotherapy resistance.Frontiers in oncology · 2025Article
- Nrf1 acts as a highly-conserved determinon for maintaining robust redox homeostasis in the eco-evo-devo process of life histories.Cell stress · 2025Review
- Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin.International journal of molecular sciences · 2024Article
- Leveraging ML for profiling lipidomic alterations in breast cancer tissues: a methodological perspective.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance continues to be one of the major challenges to cure cancer. As research in this field evolves, it has been proposed that numerous bioactive molecules might be involved in the resistance of cancer cells to certain chemotherapeutics. One well-known group of lipids that play a major role in drug resistance are the sphingolipids. Sphingolipids are essential components of the lipid raft domains of the plasma membrane and this structural function is important for apoptosis and/or cell proliferation. Dysregulation of sphingolipids, including ceramide, sphingomyelin or sphingosine 1-phosphate, has been linked to drug resistance in different types of cancer, including breast, melanoma or colon cancer. Sphingolipid metabolism is complex, involving several lipid catabolism with the participation of key enzymes such as glucosylceramide synthase (GCS) and sphingosine kinase 1 (SPHK1). With an overview of the latest available data on this topic and its implications in cancer therapy, this review focuses on the main enzymes implicated in sphingolipids metabolism and their intermediate metabolites involved in cancer drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.